- 學位論文
犬淋巴瘤預後與CD10、Bcl-6、MUM1和Bcl-2表現之相關性
The Correlation between Prognosis and Expression of CD10, Bcl-6, MUM1 and Bcl-2 in Canine Lymphomas
摘要
淋巴瘤是犬最常見的惡性腫瘤之一，形態學上與人類非何杰金氏淋巴瘤 （non-Hodgkin’s lymphoma）具有高度類似性。依照世界衛生組織分類法，瀰漫性大型B細胞淋巴瘤（diffuse large B cell lymphoma; DLBCL）為犬最常見的淋巴瘤。此外，濾泡型淋巴瘤（follicular lymphoma）、被套細胞淋巴瘤（mantle cell lymphoma）、邊緣區型淋巴瘤（marginal zone lymphoma）、與T區域型淋巴瘤（T-zone lymphoma）之臨床表徵屬於緩慢型淋巴瘤（indolent lymphoma）。 DLBCL在人類可區分為類生發中心B細胞型（germinal center B-cell-like）與類活化B細胞型（activated B-cell-like）兩種分子學亞型（molecular subtypes），前者之生物標記包含了CD10和Bcl-6，而MUM1與Bcl-2則為後者之標記。病人罹患GCB型DLBCL具有顯著較佳總存活率。 本研究為探討在犬淋巴瘤中，這四個蛋白質之免疫組織化學染色表現程度與預後之相關性。在收集的102例病例中，B細胞淋巴瘤占59例、T細胞型占41例、以及無顯著分型之淋巴瘤占2例，其中DLBCL為最常見的淋巴瘤類型。針對具有完整臨床資訊之53病例，進行CD10、Bcl-6、MUM1和Bcl-2之免疫組織化學染色。結果顯示，Bcl-2表現弱之淋巴瘤具有顯著較短的總存活時間（overall survival time），而CD10、Bcl-6、MUM1之表現皆與預後無關。此外，本研究亦證實世界衛生組織分類法之診斷與預後有顯著相關，其中緩慢型淋巴瘤不但總存活時間較非緩慢型（non-indolent）淋巴瘤長，且皆具有中等至強的Bcl-2表現程度。本研究的結果顯示，犬DLBCL並無法以CD10、Bcl-6、MUM1和Bcl-2區分為不同的分子學亞型，然而在所有種類的淋巴瘤中，Bcl-2具有預估臨床預後之潛力，其機制仍需進一步的研究加以探討。
並列摘要
Lymphoma is one of the most common malignancies in dogs. Canine lymphoma bears a morphological resemblance to non-Hodgkin’s lymphoma in the human. Diffuse large B-cell lymphoma (DLBCL), according to the World Health Organization (WHO) classification, is the most common form of canine lymphoma. Furthermore, indolent lymphomas that are characterized by a slowly progressive clinical course include follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and T-zone lymphoma. Human DLBCLs can be sorted into two molecular subtypes: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL. CD10 and Bcl-6 are biomarkers for GCB-DLBCL, while ABC-DLBCL is representative of MUM1 or Bcl-2 expression. Patients diagnosed with GCB-DLBCL show a significant better overall survival rate than those diagnosed with ABC-DLBCL. The present study is to investigate the correlation between prognosis and expression of CD10, Bcl-6, MUM1 and Bcl-2 in canine lymphomas. A total of 102 cases met the inclusion criteria, with 59 of B-cell derivation, 41 of T-cell derivation, and 2 of null-cell derivation. DLBCL was the most common diagnosis based on the WHO criteria. Immunohistochemical stain for CD10, Bcl-6, MUM1 and Bcl-2 was performed on a total of 53 cases with a complete medical and follow-up record. The results indicated that none of the markers had a correlation with prognosis with the exception of Bcl-2. Bcl-2 expression had a significantly positive correlation with overall survival time. Moreover, indolent lymphomas not only showed prolonged overall survival over non-indolent lymphomas, but also were characterized by moderate or strong levels of Bcl-2 expression. In conclusion, we did not find molecular subtypes of canine DLBCL via CD10, Bcl-6, MUM1 and Bcl-2 expression. Among these four markers, only Bcl-2 had a potential prognostic value of canine lymphomas. The mechanism of Bcl-2 remains to be determined, though.
參考文獻
延伸閱讀
- Pan, M. J., Chang, W. L., & Su, W. L. (2000). 以毛細管聚合酶鏈反應偵測並區分糞便檢體中犬小病毒及貓汎白血球缺乏症病毒. 中華民國獸醫學會雜誌, 26(1), 14-23. https://doi.org/10.7009/JTCSVS.200003.0014
- Hung, C. L. (2011). 犬肥大細胞瘤c-kit 表現與其他新興蛋白質表現之相關性 [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2011.02262
- 劉獻岳、林荀龍、黃秉琦、張惟雅、王之仰、張力天（2012）。以流式細胞儀分析健康犬及腫瘤患犬白血球CD45、CD11b及NSA之表現。臺灣獸醫學雜誌，38(4)，233-242。https://doi.org/10.7009/TVJ.201212.0233
- Ou, Y. C., Chen, J. T., Horng, Y. Y., & Yang, C. R. (2001). Expression of p53 and bcl-2 in Renal Cell Carcinoma. Mid-Taiwan Journal of Medicine, 6(1), 14-21. https://doi.org/10.6558/MTJM.2001.6(1).3
- Huang, C. M., Lin, T. H., Wang, H. J., & Chen, C. L. (2002). Expression of Costimulatory Molecules CD80 and CD86 in T Cells from Patients with Systemic Lupus Erythematosus. Mid-Taiwan Journal of Medicine, 7(1), 7-13. https://doi.org/10.6558/MTJM.2002.7(1).2